Analyst Ratings For Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Today, HC Wainwright reiterated its Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a price target of $17.00.
Some recent analyst ratings include
- 2/6/2018-HC Wainwright Reiterated Rating of Buy.
- 9/17/2017-Needham & Company LLC Reiterated Rating of Hold.
- 9/12/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 8/28/2017-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 11/4/2016-Wedbush Reiterated Rating of Neutral.
- 5/16/2016-Gabelli Reiterated Rating of Neutral.
Recent Insider Trading Activity For Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) has insider ownership of 5.50% and institutional ownership of 58.36%.
- On 1/30/2018 Jacques Dumas, Insider, sold 8,750 with an average share price of $6.22 per share and the total transaction amounting to $54,425.00.
- On 1/9/2018 Jacques Dumas, Insider, sold 7,167 with an average share price of $6.21 per share and the total transaction amounting to $44,507.07.
- On 11/29/2017 L Patrick Gage, Director, bought 3,880 with an average share price of $6.45 per share and the total transaction amounting to $25,026.00.
- On 10/31/2017 Jacques Dumas, Insider, sold 8,750 with an average share price of $6.03 per share and the total transaction amounting to $52,762.50.
- On 8/22/2017 Jacques Dumas, Insider, sold 17,500 with an average share price of $6.00 per share and the total transaction amounting to $105,000.00.
- On 8/17/2017 Jacques Dumas, Insider, sold 7,155 with an average share price of $5.86 per share and the total transaction amounting to $41,928.30.
- On 3/15/2017 L Patrick Gage, Director, bought 11,000 with an average share price of $7.49 per share and the total transaction amounting to $82,390.00.
Recent Trading Activity for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Shares of Tetraphase Pharmaceuticals closed the previous trading session at 5.34 up +0.15 2.89% with 5.139999866485596 shares trading hands.